News of Note—Bristol-Myers’ cancer vaccine, Bharat Biotech and more

non
In this week's news of note, a Bristol-Myers Squibb's cancer vaccine candidate enters human study. (Pixabay)

Here's some other vaccine news of note for the week.

> A Bristol-Myers Squibb cancer vaccine that has cured 97% of tumors in mouse studies has been approved for human trials at Stanford University. U.S. News & World Report article

> The WHO has recommended the introduction of the world’s first typhoid conjugate vaccine, Typbar-TCV, developed by Bharat Biotech, for infants and children over 6 months of age in typhoid-endemic countries. Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> Sellas touted phase 2b results that showed its cancer vaccine NeuVax’s ability in prolonging disease-free survival when combined with Herceptin in a group of breast cancer patients. Endpoints News article

> The Global Health Innovative Technology Fund has awarded the University of Florida and partners in the U.S. and Japan $3.2 million to develop a new malaria vaccine. Release

> Through a HK$98.75 ($12.6 million) fund, Hong Kong will provide free HPV vaccination to girls from low-income families. South China Morning Post article

> Archivel Farma has signed a deal with Laboratorios Silanes to develop and commercialize Ruti, a therapeutic vaccine against tuberculosis, in Mexico. Release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.